IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Prevention and treatment of symptoms in chronic obstructive airway disorders with reversible airflow limitation such as bronchial asthma and especially chronic bronchitis with or without emphysema.
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.